152 related articles for article (PubMed ID: 38705774)
21. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
[TBL] [Abstract][Full Text] [Related]
22. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
[TBL] [Abstract][Full Text] [Related]
24. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
25. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
26. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.
Mottl AK; Alicic R; Argyropoulos C; Brosius FC; Mauer M; Molitch M; Nelson RG; Perreault L; Nicholas SB
Am J Kidney Dis; 2022 Apr; 79(4):457-479. PubMed ID: 35144840
[TBL] [Abstract][Full Text] [Related]
27. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
28. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
29. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
Rangaswami J; Bhalla V; de Boer IH; Staruschenko A; Sharp JA; Singh RR; Lo KB; Tuttle K; Vaduganathan M; Ventura H; McCullough PA;
Circulation; 2020 Oct; 142(17):e265-e286. PubMed ID: 32981345
[TBL] [Abstract][Full Text] [Related]
30. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.
Zanchi A; Jehle AW; Lamine F; Vogt B; Czerlau C; Bilz S; Seeger H; de Seigneux S
Swiss Med Wkly; 2023 Jan; 153():40004. PubMed ID: 36652726
[TBL] [Abstract][Full Text] [Related]
31. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Mende CW
Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
[TBL] [Abstract][Full Text] [Related]
32. Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.
Mayne KJ; Hanlon P; Lees JS
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38699995
[TBL] [Abstract][Full Text] [Related]
33. Advances in the management of chronic kidney disease.
Chen TK; Hoenig MP; Nitsch D; Grams ME
BMJ; 2023 Dec; 383():e074216. PubMed ID: 38052474
[TBL] [Abstract][Full Text] [Related]
34. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Diabetes Care; 2022 Dec; 45(12):3075-3090. PubMed ID: 36189689
[TBL] [Abstract][Full Text] [Related]
35. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
[TBL] [Abstract][Full Text] [Related]
36. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020.
Sherrill CH; Hwang AY
Ann Pharmacother; 2024 Mar; 58(3):248-254. PubMed ID: 37323006
[TBL] [Abstract][Full Text] [Related]
37. GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice.
Romera I; Rubio-de Santos M; Artola S; Suárez Fernández C; Conget I
Adv Ther; 2023 Apr; 40(4):1418-1429. PubMed ID: 36821026
[TBL] [Abstract][Full Text] [Related]
38. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
39. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
Nicholas SB; Daratha KB; Alicic RZ; Jones CR; Kornowske LM; Neumiller JJ; Fatoba ST; Kong SX; Singh R; Norris KC; Tuttle KR
Diabetes Obes Metab; 2023 Oct; 25(10):2970-2979. PubMed ID: 37395334
[TBL] [Abstract][Full Text] [Related]
40. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
Albakr RB; Sridhar VS; Cherney DZI
Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
